LigaChem Biosciences: A Shareholder-Returns Laggard in a High-Tech Wrapper

South Korea's leading ADC biotech has won deals with global pharma giants, but its shareholders are still waiting for tangible returns.

Company Overview

LigaChem Biosciences is South Korea's pre-eminent antibody-drug conjugate (ADC) company, built around its proprietary ConjuAll™ linker-payload platform. Listed on the KOSDAQ — South Korea's technology-focused stock exchange — the firm has secured a string of licensing agreements with global pharmaceutical giants, cementing its reputation as a flagship of the Korean biotechnology sector. It ranks among KOSDAQ's largest companies by market capitalisation, and its ADC capabilities have attracted persistent interest from major multinational drugmakers, including Janssen (Johnson & Johnson) and AstraZeneca.

Yet LigaChem remains a growth-stage company in the truest sense. It generates neither substantial operating profit nor stable cash flows, and the gap between market expectations and reality on shareholder returns — dividends and share buybacks in particular — has long been a source of tension. As South Korea's government-backed "Value-Up" programme, designed to address the chronic undervaluation of Korean equities known as the "Korea Discount", extended its reach into the pharmaceutical and biotechnology sector, LigaChem found itself squarely in the spotlight. When fellow KOSDAQ biotech Alteogen broke new ground by initiating a dividend, the question of whether LigaChem would follow suit became one of the market's most closely watched questions.

Business Model and Financial Performance

*Core business: the ADC platform and technology licensing*

LigaChem's business rests on two pillars. The first is licensing its ConjuAll™ platform to global pharmaceutical companies, collecting upfront fees and milestone payments as drugs advance through development. The second is advancing its own pipeline through clinical trials to maximise value before or at the point of partnering. Deals with the likes of Janssen and AstraZeneca have provided external validation of its technology.

*Annual financial results*

As is typical of licensing-driven biotechs, LigaChem's annual results fluctuate sharply depending on when contract fees are recognised. The timing of new licensing deals and clinical progress directly determines revenues and the bottom line.

Year | Revenue (approx., KRW bn) | Operating profit | Net profit | Key developments

2021 | ~30 | Loss | Loss | Early licensing deals expand

2022 | ~40 | Loss | Loss | ConjuAll™ platform refined

2023 | ~70 | Near breakeven | Loss | Major licensing contract signed

2024 | ~100+ | Modest profit | Improving | Global deal diversification

2025 | Significant growth | Volatile | Milestone-dependent | Value-Up pressure intensifies

*Note: LigaChem's reported figures vary materially depending on the accounting treatment of licensing fees and milestones. Precise figures should be verified against the company's official filings.*

*Cash flow and capacity for shareholder returns*

Research and development spending remains high relative to revenues, as one would expect for a clinical-stage biotech. Large upfront licensing payments can produce a temporarily healthy cash position, but sustained free cash flow is limited by ongoing clinical investment needs. This structural constraint lies at the heart of the market debate over whether LigaChem can, or should, begin returning cash to shareholders.

Value-Up: A Chronology

*2024 — The Value-Up programme reaches the biotech sector*

When South Korean financial regulators formally launched the corporate Value-Up programme to address the Korea Discount, investor expectations for shareholder returns spread from the main KOSPI board to KOSDAQ companies. As one of KOSDAQ's largest biotechs, LigaChem was a natural focal point. Market participants began calling on the company — already globally recognised for its ADC technology — to demonstrate leadership on shareholder returns as well.

*July 2025 — A stark public warning on Korea's biotech environment*

In July 2025, LigaChem's management made headlines by issuing a blunt public warning about the operating environment for Korean biotechnology. The phrase circulating in the industry — roughly translated as "miss this moment and Korean biotech is finished" — was interpreted less as corporate despair and more as a forceful call on regulators to improve the domestic framework for drug development, at a moment when global ADC competition was intensifying rapidly. While not directly related to the Value-Up programme, it was noted as evidence of management's willingness to communicate openly.

*December 2025 — The "treasury share alliance" spreads*

By December 2025, at least 25 companies in the pharmaceutical and biotech sector held treasury shares (bought-back stock held by the company itself) worth 10 billion won (approximately US$7 million) or more. LigaChem was reported to be part of this broader movement, and market scrutiny of its specific intentions for those shares intensified accordingly.

*February 2026 — Alteogen's dividend triggers pressure on peers*

In February 2026, Alteogen became the first significant KOSDAQ biotech to declare a dividend, setting a precedent for the sector. Financial analysts and media immediately turned their attention to LigaChem and ABL Bio, asking whether either would follow suit. LigaChem was widely described as the most likely "next Alteogen" — the company most capable and most expected to be the next mover on shareholder returns.

*Late February 2026 — Treasury shares briefly in focus*

Later that month, coverage of biotech share cancellations — Bionote announced the retirement of 650,000 treasury shares — brought LigaChem's own treasury share strategy back into the conversation, though the company had yet to announce specific plans.

*April 2026 — Named as a candidate for KOSDAQ's "3000" Value-Up push*

As debate gathered around pushing the KOSDAQ index above the 3,000-point threshold, LigaChem was repeatedly cited as a prime Value-Up candidate within the biotech space. Its global contract track record and technological credentials were seen as providing a solid fundamental basis for a re-rating.

*May 2026 — Shareholder letter amid a sector-wide sell-off*

In May 2026, a sharp market-wide decline in biotech equities prompted LigaChem, alongside Celltrion and Orum Therapeutics, to write directly to shareholders. The letters emphasised that the companies' underlying fundamentals remained intact and that the sell-off did not reflect any deterioration in business prospects. The gesture was interpreted as going beyond simple share-price defence — it was widely read as a commitment to transparent investor relations, and thus as part of the broader Value-Up ethos.

Challenges and Assessment

*Key challenges ahead*

For LigaChem to become a genuine participant in the Value-Up programme, several structural problems must be addressed.

First, and most fundamentally, the company must stabilise its revenues and build a reliable pool of capital available for distribution. A business model that depends on the irregular timing of licensing milestones makes it structurally difficult to commit to a regular dividend. Successful clinical results and additional major deals are prerequisites for building the cash generation needed.

Second, the company must articulate a clear, public shareholder-return policy. With Alteogen having set a precedent, investor pressure is growing for LigaChem to publish a concrete roadmap — covering when dividends might begin, what the buyback and cancellation plan looks like, and what the medium-term return targets are.

Third, despite its technology being internationally recognised, LigaChem continues to suffer from the Korea Discount: a perception that its valuation is suppressed relative to comparable Western or Japanese peers. Redressing this will require both more aggressive global investor-relations activity and credible signals on shareholder returns.

*Overall assessment*

The market's verdict on LigaChem's Value-Up progress can be summarised as "potential unrealised." Its ADC capabilities and its record of signing with top-tier global partners speak for themselves. However, the absence of dividends, the lack of transparency on treasury-share intentions, and the dearth of tangible shareholder-return milestones mean the company has yet to earn the designation of a Value-Up leader.

On the positive side, management's willingness to communicate directly — through shareholder letters and frank public statements — deserves credit. The expectation in the market is that, as LigaChem's technology matures and its cash flows strengthen, its approach to returning capital to shareholders will mature alongside it.

Controversies and Structural Limitations

*Can't pay, or won't? A structural dilemma*

The central controversy surrounding LigaChem's shareholder returns is whether the company is genuinely unable to pay a dividend given its business model, or whether it is capable of doing so but has chosen not to. The structural argument — that R&D-intensive biotechs inherently cannot promise stable distributions — has merit. But critics point out that when licensing deals have brought in hundreds of billions of won in upfront payments, the absence of any serious dividend discussion looks less like necessity and more like a lack of intent.

*Opaque treasury-share policy*

Even as a broader "treasury share movement" has taken hold across the pharmaceutical and biotech sector, LigaChem's holdings and intentions have not been clearly disclosed. Holding treasury shares is of limited value to investors if there is no credible commitment to retire them.

*An awkward fit with the Value-Up framework*

The government's Value-Up programme was originally conceived to address companies trading below book value — those with a price-to-book ratio below 1. LigaChem, by contrast, commands a substantial premium to book, reflecting the market's valuation of its technology. This means the company's Value-Up story is really about building investor confidence through shareholder returns, rather than the standard low-valuation-uplift narrative — a distinction that makes simple comparisons with other Value-Up participants somewhat misleading.

*Competitive risk and valuation volatility*

The global ADC market is becoming crowded rapidly. Clinical failures or the emergence of superior competing technologies could trigger sharp drops in LigaChem's valuation — as the May 2026 sell-off illustrated. This inherent volatility makes a stable, long-term shareholder-return policy harder to design and harder to commit to.

Summary Data

*Price-to-book ratios for KOSDAQ biotechs reflect substantial technology premiums and fluctuate widely; precise figures should be checked against filings at each relevant date.*

LigaChem Biosciences: A Shareholder-Returns Laggard in a High-Tech Wrapper

ABL Bio: A Biotech's Unconventional Path to Value Creation

Simtech: Riding the AI Wave, but Governance Clouds the View

Samchundang Pharma: A Cautionary Tale for Korea's Market Reform Drive